ClinicalTrials.gg
Not yet recruitingNCT07447739Updated Mar 3, 2026

Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?

A Phase 2 interventional study of Betamethasone in Respiratory Distress Syndrome (RDS) and Bronchopulmonary Dysplasia (BPD), sponsored by Khang Nguyen. Not yet recruiting at 1 site in United States. Open to participants aged Up to 28 Weeks. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Khang Nguyen · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
Up to 28 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Planned enrollment
81st of 250
100 · median 52
Started
2026
with 14 others
Phase 2
74 of 324
8 open now
Primary completion
2027-03
later than 19 of 55 live
Registered
317th of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 81st largest by planned enrollment of the 250 interventional ones that give a count, is one of 15 that started in 2026, is one of 74 in phase 2, reaches primary completion later than 19 of the 55 other live ones, and was the 317th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: Up to 28 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to determine if giving a steroid medication (specifically, betamethasone) after birth can help extremely premature babies (born before 28 weeks) come off breathing machines safely and reduce their risk of chronic lung disease associated with prematurity. Only babies who meet treatment criteria will receive this medication. Babies who do not meet treatment criteria will not receive medication.

The main questions it aims to answer are:

  • Does betamethasone make it easier for babies to come off a breathing machine?
  • Does betamethasone cause any harmful side effects on growth or development?

All babies in this study will:

  • Receive standard NICU care, with or without betamethasone
  • Have their progress, growth, and development followed over time
Read the detailed description

Babies born extremely early (before 28 weeks of pregnancy) often have very immature lungs and usually need a breathing machine to stay alive. Many of these babies develop a chronic lung disease associated with prematurity called bronchopulmonary dysplasia, which can cause breathing problems that may last for months or years.

Doctors sometimes use steroid medications after birth to help reduce lung inflammation, make breathing easier, and help babies come off the ventilator sooner. One of these medications is betamethasone. Betamethasone is already commonly given to mothers before preterm birth to help babies' lungs mature.

At our hospital, betamethasone has been given after birth for more than 20 years to help some premature babies breathe better and come off a breathing machine. This study will help us learn how well this medicine works and possible side effects.

All babies born before 28 weeks gestation will be approached for enrollment in this study. Babies with lung disease severe enough according to predetermined criteria will receive betamethasone. Babies who dont have severe lung disease will not receive betamethasone.

03

Conditions studied

  • Respiratory Distress Syndrome (RDS)
  • Bronchopulmonary Dysplasia (BPD)

Keywords

  • respiratory distress syndrome
  • bronchopulmonary dysplasia
  • extremely low gestational age neonates
  • postnatal corticosteroids
  • betamethasone
04

Who can participate

Ages eligible
Up to 28 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born at less than 28 weeks gestation age
  • Admitted to WMC NICU prior to day of life 35

Exclusion criteria

Exclusion Criteria:

  • Infants with major congenital or chromosomal abnormalities.
  • Death prior to DOL 8.
  • Previous exposure to postnatal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Betamethasone arm

    Infants who meet clinical criteria will receive postnatal betamethasone

    Drug: Betamethasone

  • No intervention
    Comparison

    Infants who do not meet criteria to receive treatment

Interventions

  • Infants who meet clinical criteria will receive a 5-day course of postnatal betamethasone: 0.125 mg/kg/dose IM every 24 hours for 3 days then 0.0625 mg/kg/dose IM every 24 hours for 2 days

06

What researchers measure

Primary outcomes

  1. The rate of successful respiratory weaning

    * Defined by a 20% reduction from baseline in mean airway pressure or FiO2 if patient remains intubated * or successful extubation and maintenance of extubation for 7 days after betamethasone completion

    Time frame: From initiation of treatment until 7 days after treatment completion

Secondary outcomes

  1. The incidence of adverse events

    The incidence of hyperglycemia (\>150 mg/dL) during administration period

    Time frame: During betamethasone administration period (5 days)

  2. The incidence of adverse events

    The incidence of hypertension (requiring medication) anytime during hospitalization

    Time frame: From the time of initiation of betamethasone until the time of NICU discharge or 52 weeks of age, whichever comes first

  3. The incidence of adverse events

    The incidence of gastrointestinal perforation (during or less than 72 hours after treatment completion)

    Time frame: During betamethasone administration period and up to 72 hours after completion of betamethasone administration

  4. The incidence of adverse events

    The incidence of culture-positive infection that requires treatment

    Time frame: From the time of initiation of betamethasone until the time of NICU discharge or 52 weeks of age, whichever comes first

  5. The incidence of mortbidities associated with extreme prematurity

    The incidence of * Severe intraventricular hemorrhage * Periventricular leukomalacia * Retinopathy of prematurity * Hemodynamically signifcant patent ductus arteriosus

    Time frame: From admission until the time of NICU discharge or 52 weeks of age, whichever comes first

  6. Anthropometric measurements

    weight at the time of discharge (in grams and percentile rank using Fenton growth curve 2013 for gestational age) and at 24 months corrected age (in grams and their corresponding percentile rank for age using CDC growth chart 0-36 months)

    Time frame: From discharge to 24 months corrected age

  7. Anthropometric measurements

    length at the time of discharge (in centimeters and percentile rank using Fenton growth curve 2013 for gestational age) and at 24 months corrected age (in centimeters and their corresponding percentile rank for age using CDC growth chart 0-36 months)

    Time frame: From discharge to 24 months corrected age

  8. Anthropometric measurements

    Head circumference at the time of discharge (in centimeters and percentile rank using Fenton growth curve 2013 for gestational age) and at 24 months corrected age (in centimeters and their corresponding percentile rank for age using CDC growth chart 0-36 months)

    Time frame: From discharge to 24 months corrected age

  9. Neurodevelopmental outcomes

    the results of evaluation utilizing the Bayley Scales of Infant Development. The minimum score is 40 and the maximun score is 160, with a higher score represents better outcome. The score of 100 is average, and 15 points represents 1 standard deviation either way.

    Time frame: at 24 months corrected age

  10. Bronchopulmonary dysplasia diagnosis

    Using the 2019 Jensen criteria: * Grade 1 - nasal cannula ≤2 L/min * Grade 2 - nasal cannula \>2 L/min or noninvasive positive airway pressure * Grade 3 - invasive mechanical ventilation

    Time frame: at 36 weeks corrected age

07

Study locations

1 site
  • Maria Fareri Children's Hospital at Westchester Medical Center
    Valhalla, New York 10595, United States
08

References and documents

Publications

  • DeCastro M, El-Khoury N, Parton L, Ballabh P, LaGamma EF. Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study. J Perinatol. 2009 Apr;29(4):297-304. doi: 10.1038/jp.2008.194. Epub 2008 Dec 4. PubMed 19052552 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Mar 2027, 11 months later.

Of 31 non-industry phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 44. This study's planned 11 months is below that.

Counting every sponsor, half of 59 studies reached it within 18 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Mar 3, 2026
StartEst.
Apr 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2029
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447739
Lead sponsor
Khang Nguyen
Responsible party
Khang Nguyen (MD, New York Medical College) — Sponsor-investigator
First posted
Mar 3, 2026
Start date
Apr 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2029 (estimated)
Last update
Mar 3, 2026

Study contacts

Jordan Kase, MD
Contact
jordan.kase@wmchealth.org
914-493-8558
Wendi Gu, MD
Contact
wendi.gu@wmchealth.org
914-493-8558
Jordan Kase, MD
principal investigator · Maria Fareri Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Betamethasone

Start the discussion